Evofem Biosciences (EVFM) presents a deeply negative liquidation posture as of March 31, 2026. The MFFAIS-computed cash liquidation value is -$84.5M, liquid liquidation value is -$72.0M, and operating liquidation value is -$70.9M. These figures reflect the structural asymmetry of a balance sheet where haircutted assets are vastly exceeded by obligations carried at face value. Management discloses a working capital deficit of $72.7M and an accumulated deficit of $902.9M as of period end. Cash and cash equivalents totaled approximately $2.4M (including $0.9M restricted), which management explicitly states is insufficient to fund operations for the next 12 months, constituting a going concern. The Baker Bros. Purchase Agreement remains in contested default with the Future Pak Designated Agent having accelerated approximately $107.0M in outstanding principal and accrued interest — a contingent claim not fully reflected in the balance sheet at face value but which would be catastrophic to any recovery scenario. The Adjuvant Notes were extended post-period (April 10, 2026 Fourth Amendment) to mature six months after April 10, 2026, compressing the near-term liability timeline. The SOLOSEC contingent liability — noncurrent component — declined materially from $4.6M (December 31, 2025) to $1.1M (March 31, 2026), reducing the obligation stack modestly. The Rush Royalty contingent liability of $1.9M was reversed in 2025 after the Rush Patent was determined to have expired on its original date; residual exposure ranges from a $0.9M potential gain (refund of overpaid royalties) to a $2.3M potential loss if Rush University pursues payment for the OGIE period — neither is currently accrued. Preferred stock (Series E-1, F-1, G-1) carries 125% liquidation premiums plus Black-Scholes Value components upon dissolution, creating layered priority claims above common equity that further compress any equity recovery to zero or negative. Approximately 85% of trade payables were greater than 90 days past due as of March 31, 2026, signaling acute vendor stress and elevated litigation risk from collections actions. The TAG_CONTEXT list contains no XBRL tags for this filing period, preventing tag-level quantitative corroboration; all figures above are sourced from narrative disclosures and the MFFAIS metadata. Filing discusses Baker Bros. acceleration claim (~$107M), Series E-1/F-1/G-1 liquidation preference mechanics, and SOLOSEC contingent liability reduction in MD&A and footnotes but none are separately tagged in XBRL per the empty TAG_CONTEXT.
▼ Community Notes